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Abstract 
 
Background: Astragaloside, which is one of the main components of Astragalus membranaceus, has been widely used 
in the treatment of congestive heart failure in China, and it can protect cardiomyocytes. Its mechanism of action remains 
unclear. Therefore, the present study was carried out to investigate the influence of astragaloside on rat cardiomyocytes 
stimulated with endothelin-1 (ET-1), and explored the underlying mechanism. 
Materials and Methods: ET-1 was used to stimulate primary rat cardiomyocytes and establish a cardiomyocyte 
hypertrophy model. Different astragaloside doses were administered in combination with ET-1. Cardiomyocyte 
hypertrophy and apoptosis were examined using transmission electron microscopy (TEM) and flow cytometry, 
respectively. The molecular mechanism was explored by analyzing the mRNA of the vitamin D receptor (VDR), 
cytochrome P450 family 27 subfamily B member 1(CYP27B), cytochrome P450 family 24 subfamily A member 
1(CYP24A) and renin mRNA levels by quantificational real-time polymerase chain reaction(qRT-PCR). 
Results: Rat cardiomyocyte hypertrophy model was established successfully. Astragaloside administration significantly 
affected cell apoptosis and significantly inhibited ET-1-induced cardiomyocyte hypertrophy in a dose-dependent manner. 
Astragaloside treatment affected the expression of signaling molecules in the vitamin D axis. 
Conclusion: Astragaloside inhibits ET-1-induced cardiomyocyte hypertrophy. This effect can be reversed by regulating 
the levels of the relevant factors in the vitamin D axis. 
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Introduction 
 
Myocardial remodeling is caused by a complex series of molecular and cellular mechanisms (Colucci, 1997), that 
result in an increase in cardiomyocyte diameter via broadening or linear expansion accompanied by cardiomyocyte 
necrosis and apoptosis (Ding et al., 2009). 
Recently, many studies have demonstrated an association between the plasma vitamin D level and the occurrence of 
cardiovascular disease (Muscogiuri et al., 2016, Pilz et al., 2016). Vitamin D deficiency can result in activation of the 
renin-angiotensin-aldosterone system (RAAS)(Ferder et al., 2013). Vitamin D receptor (VDR) knockout mice  and 
1α-hydroxylase knockout mice showed individual myocyte enlargement and an elevation in natriuretic peptide 
expression (Glenn et al., 2016). Additionally, the renin expression level is increased in systemic and cardiac RAAS 
activation (Xiang et al., 2005, Zhou et al., 2008). Renin mRNA and protein expression is increased in the kidneys, and the 
cardiomyocytes appear hypertrophy and apoptosis(Bae et al., 2013). Active vitamin D acts on the VDR to interfere with 
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the function of the renin promoter and inhibit renin gene transcription activation. Thus, vitamin D can inhibit the 
expression of the renin gene to regulate the RAAS (Nakane et al., 2007, Li et al., 2002). Additionally, vitamin D not only 
inhibits the generation of proinflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), 
but also increases the expression of anti-inflammatory cytokines, such as interleukin 10 (IL-10) (Barker et al., 2014, Liu 
et al., 2011).Vitamin D also has antioxidant effects (Lee et al., 2015) that improve myocardial metabolism, protect the 
mitochondria (Mukherjee et al., 1981), and inhibit apoptosis to protect the myocardium (Yao et al., 2015). 
Astragalus membranaceus is a commonly used traditional Chinese herb that contains flavonoids, saponins, and 
other active ingredients that have wide pharmacological actions, including anti-diabetic, anti-hypertensive, 
anti-inflammatory, and cardioprotective effects as well as the prevention of heart failure(Huang et al., 2016, Li et al., 
2017).Astragaloside(AST) is one of the main components of Astragalus membranaceus which could modulate the RAAS 
and inhibit cardiomyocyte hypertrophy and apoptosis to protect the heart (Shi et al., 2009, Zhang et al., 2015).  
Using the Arrowsmith method（http://arrowsmith.psych.uic.edu/cgi-bin/arrowsmith_uic/start.cgi）, we found a 
correlation between Astragalus and vitamin D in the treatment of myocardial hypertrophy. Given this background, we 
hypothesized that the vitamin D axis played a vital role in the mechanism of astragaloside in treatment of cardiomyocyte 
hypertrophy. The present investigation was designed to study whether astragaloside exerted its anti-hypertrophic actions 
through the vitamin D axis. 
 
Materials and Methods 
Primary culture of rat cardiomyocytes 
 
One-to-three-day-old newborn Sprague Dawley rats were purchased from the Animal 
enter of the Third Military Medical University (Chongqing, China). The ventricular myocardium was prepared as 
described previously (Menaouar et al., 2014). Briefly, the ventricular myocardium was excised, cut into small pieces, 
and washed three times with cold phosphate-buffered saline (PBS, ZSGB-BIO, China). Then, the tissues were digested 6 
times for each 5 min at 37oC with 0.125% (w/v) trypsin (Beyotime, China). An equal volume of cold Dulbecco’s 
modified Eagle’s medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco, USA) containing 10% (v/v) fetal bovine serum 
(FBS, Gibco, USA) was added to terminate the digestion. The cells were collected and centrifuged for 10 min at 1000 
rpm at room temperature. Then, the cells were collected and suspended in DMEM/F12 complete medium containing 1% 
antibiotics (penicillin/streptomycin, Gibco, USA) and 10% (v/v) FBS and cultured in an incubator at 37oC with 5% CO2 
and saturated humidity. The culture medium was renewed after 48 h, and the cells were cultured for an additional 24 h. 
Then, the medium was changed to serum-free DMEM/F12, and the cardiomyocytes were randomly divided into 6 groups 
as follows: 1. Control group (PBS); 2. ET-1 (10-8 mol/L, Sigma, USA) pretreatment group; 3. VD group (ET-1, 10-8 mol/L 
+ Vitamin D,10-8 mol/L, Sigma, USA) ; 4. AST (10μg/mL) group (ET-1, 10-8 mol/L + AST, 10μg/mL, Sigma, USA); 5. 
AST (20μg/mL) group (ET-1, 10-8 mol/L+AST, 20μg/mL, Sigma, USA); and 6. AST (40μg/mL) group 
(ET-1,10-8mol/L+AST,40μg/mL, Sigma, USA). The experiments were performed after 24 h of treatment with the 
indicated drugs. 
 
Immunohistochemistry 
 
The cell density was adjusted to 2×104 cells/mL, and the cells were cultured on a cover glass. Then, the cover 
glass was fixed with 4% paraformaldehyde, cleared with PBS containing 0.5% Triton X-100, treated with 3% hydrogen 
peroxide (H2O2) in methanol to quench endogenous peroxidase activity, and blocked in 6% goat serum. The samples 
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were incubated overnight with an α-actin antibody (Abcam, USA; diluted1:200) at 4℃. Then, the samples were 
incubated with a biotinylated secondary antibody (Abcam, USA; diluted 1:200) at 37oC for 30 min. HRP-labeled 
streptavidin and the HRP substrate were added, and the samples were incubated at 37oC for 30 min. A 
3,3’-diaminobenzidine (DAB) (ZSGB-BIO, China) substrate system was used for color development in the dark. After 
counterstaining with hematoxylin, the sections were dehydrated for 5 min, dehydrated with an alcohol gradient, cleared 
with xylene, and mounted with neutral mounting medium. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
The cells were digested and collected. RNA extraction was performed using the TRIzol reagent (Qiagen) according 
to the manufacturer's recommendations. Reverse transcription (RT) was conducted with random primers, and qRT-PCR 
was performed to examine the VDR, vitamin D 27-hydroxylase (CYP27B), vitamin D 24-hydroxylase (CYP24A) and 
renin mRNA expression levels; the primer sequences are listed in Table   1. The qRT-PCR amplification conditions were 
as follows: 94oC for 4 min, followed by 35 cycles of 94oC for 20 sec, 60oC for 30 sec, and 72oC for 30 sec. The analysis 
was repeated three times for each sample.  
 
Table 1: Primers and fluorescent probes used in the fluorescent quantitative PCR systems 
Name of the primer Sequence (5’-3’) Amplified length (bp) 
VDR F  CCCGACCCTGGTGACTTTG 
188 
VDR R  CGGTTGTCCTTGGTGATGC 
CYP27B F AGTGTTGAGATTGTACCCTGTGG 
126 
CYP27B R TCCCTTGAAGTGGCATAGTGA 
CYP24 F ACCAAAGTGTGGCAGGCAC 
168 
CYP24 R GACAGCGGCGTACAGTTCC 
Renin F CTGCTCAGGCTGTTGATGGA 
168 
Renin R AGTGAAAGTTGCCCTGGTAATG 
Actin F CCCATCTATGAGGGTTACGC 
150 
Actin R TTTAATGTCACGCACGATTTC 
 
Transmission electron microscope 
 
The cells were collected and fixed with glutaraldehyde/osmium tetroxide fixative. The samples were cut into a 
series of semi-thin sections and embedded. The sections were stained with compound dye (0.25% sodium borate: 0.25% 
basic fuchsin, 1:1) and cut into ultrathin sections after observation using a microscope. The ultrathin sections were put on 
a copper wire mesh and attached with a film prepared using a 0.45% Fonnvar solution. Then, the samples were dried on 
filter paper, stained with uranyl acetate and lead citrate, and examined using a transmission electron microscope (Royal 
Philips Tecnai-10, the Netherlands). 
 
Flow cytometry 
 
The cells were harvested by enzymatic digestion and washed in PBS. A total of 3×105 cells were collected. The 
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cells were incubated with 50 μL of 7-AAD staining solution (BD) at room temperature for 10 min in the dark. The 
solution was then centrifuged, the supernatant was discarded, and the cells were resuspended in 450 μL of binding 
buffer. The solution was incubated at room temperature for 10 min in the dark after the addition of 1 μL of Annexin 
V-PE staining solution. Cell apoptosis was analyzed by flow cytometry (BD Influx flow cytometer, USA) after cooling 
the solution in an ice bath. The BD FACSTM software was used to store and retrieve the data. 
 
Statistical  
 
Statistical analysis of the experimental data was performed using the SPSS software 17.0 (SPSS, Chicago, IL, USA). 
Measurement data were presented as the mean± standard deviation to compare the means of two variables (not groups) 
for the survey data. One-way ANOVA was used to compare differences among groups. A p-value<0.05 was considered 
significant. 
 
Result 
Identification of rat cardiomyocytes 
 
During the initial inoculation period, the primary cardiomyocytes were transparent and round. The cells adhered to 
the culture dish approximately 24 h after inoculation. Non-adherent cells and impurities were eliminated with time and 
medium changes. After adherence, the cells began to spread and divide. The cells were fusiform or polygonal in shape 
with the nucleus located in the center of the cell. Cardiomyocytes were identified by immunohistochemical staining for 
rat α-actin (Fig. 1).  
        
                  100 X                                         400 X 
Figure 1: Identification of primary cardiomyocytes of rats 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
The VDR, CYP24A, CYP27B and renin mRNA expression levels were evaluated by qRT-PCR. For each gene, the 
primer sets amplified a unique PCR product with a single-peak dissociation curve. The amplification efficiency of the 
PCR reactions was higher than 95%. Relative quantification of the PCR results indicated that the VDR and CYP27B 
mRNA expression levels were significantly reduced in the ET-1 group compared with the control group, whereas the 
CYP24A and renin mRNA expression levels were significantly increased in the ET-1 group (P<0.05). The mRNA levels 
of all genes in VD group were similar to the expression levels in the control group (P>0.05).  AST groups had an effect 
similar to VD group. Thus, astragaloside and vitamin D may partially counteract the effects of ET-1 on the mRNA levels 
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of the candidate genes in a dose-dependent manner (Fig. 2). 
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Figure 2: ET-1-induced cardiomyocyte hypertrophy was attenuated by AST in neonatal rat cardiomyocytes. (A–D) The 
mRNA expression levels of VDR, CYP27B, CYP24 and renin were evaluated by qRT-PCR analysis in cardiomyocytes 
exposed to control (PBS), ET-1 (10-8mol/L), VD and AST (10-40μg/mL). The data are expressed as the mean±sd. 
*p<0.05, **p<0.01 versus controls, #p<0.05, and ##p<0.01 versus the ET-1 group. 
 
Cardiomyocyte hypertrophy 
 
Ultrathin sections of the cells in each group were observed by TEM (Fig. 4). The observed ultrastructures revealed 
that the cardiomyocytes in the control group had a uniform nucleoplasm and smooth nuclear membranes. The 
mitochondrial cristae in the cardiomyocytes were arranged in an orderly and dense manner. After treatment with ET-1, 
the cells exhibited marginalized and aggregated chromatin and crinkled and distorted nuclear membranes; we also 
observed dense bodies in the cytoplasm. The cristae of the mitochondria were disordered, loose, and broken. When ET-1 
and vitamin D were co-administered, the cells resembled the control group cells. When ET-1 and AST were 
co-administered, the area of the nuclei increased. The pathological changes in the mitochondria of the rat cardiomyocytes 
improved, and the chromatin aggregated in the middle of the nuclei (Fig. 3). 
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Figure 3: Astragaloside effect on mice cardiomyocyte. Transmission electron microscope. (A-F show group Ctrl, ET-1, 
VD, AST(10-40ug/ml)) 
 
Flow cytometry 
 
To examine the effect of AST on ET-1-induced cell death, apoptosis was examined by flow cytometry. The flow 
cytometry results indicated that the cell apoptosis rates in the control group, ET-1 group, ET-1 +VD group and ET-1 + 
AST group were 7.45±0.13%, 14.41±0.11%, 8.3±0.44%, 13.35±0.27%, 9.77±0.07% and 8.21±0.07%, respectively. A 
significant difference was observed in the survival rate between the control group and each experimental group (P<0.01) 
(Fig. 4). 
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Figure 4: Effect of AST on ET-1-induced cell apoptosis.(A-F show group Ctrl, ET-1, VD, AST(10-40ug/ml)) .Figure G 
shows the rate of cardiomyocyte apoptosis. Data are expressed as means ± sd. *p < 0.05, **p < 0.01 versus control, #p < 
0.05, ##p < 0.01 versus ET-1 group. 
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Discussion 
 
Cardiomyocyte hypertrophy is an adaptive response to a variety of cardiovascular stimuli, such as the hemodynamic 
load (Devereux et al., 1983), growth factors(Karpanen et al., 2008) and hormones(Hu et al., 2005). Chronic 
cardiomyocyte hypertrophy may lead to cardiac arrhythmia (Ehses et al., 2000), myocardial infarction, heart failure, and 
even death; therefore, cardiomyocyte hypertrophy is considered an independent risk factor for an increase in 
cardiovascular morbidity and mortality(Mahdy Ali et al., 2012). 
Renin is a rate-limiting step in angiotensin II (Ang Ⅱ) production. Renin not only initiates the RAAS chain reaction 
with angiotensinogen (Yoshida et al., 2014), but also activates the prorenin receptor-activated intracellular signal 
transduction pathway, which is dependent on Ang Ⅱ  production. Thus, renin plays a vital role in promoting 
inflammation and proliferation, leading to cardiomyocyte hypertrophy and hyperplasia(Saris et al., 2006). A large 
number of studies have confirmed that activated RAAS regulates cardiomyocyte growth and apoptosis by endocrine and 
paracrine effects (Weir and Dzau, 1999)and that activate proinflammatory cytokines and exacerbate the inflammatory 
response (Sciarretta et al., 2009). Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor 
blockers (ARBs) play important roles in the treatment of chronic heart failure and coronary artery disease (Cohn, 2007, 
Bavry et al., 2014). However, these drugs failed to elicit the desired results (Lother and Hein, 2016). Currently, an 
emerging field is seeking to directly regulate the synthesis and release of renin through endogenous metabolic 
intermediates that block RAAS from the source. Vitamin D and it’s analogues may be novel drugs for the prevention and 
treatment of chronic cardiovascular disease via the inhibition of the secretion of renin and the systemic and local 
RAAS(Pourdjabbar et al., 2013). 
Astragaloside has wide pharmacological actions, including anti-diabetes, anti-hypertension, anti-inflammation (Xie 
and Du, 2011, Wang et al., 2016), cardiomyocyte protection, and anti-heart failure (Luo et al., 1995). Astragaloside 
regulates cardiomyocytes mainly by inducing NO release, preventing lipid peroxidation (Wang et al., 2015), eliminating 
oxygen free radicals, reducing oxidative damage in the body, improving the vigor of the myocardial sarcoplasmic 
reticulum Ca2+-ATPase (SERCA), stabilizing the intracellular Ca2+ concentration, inhibiting the overload of intracellular 
calcium(Meng et al., 2005, Lu et al., 1999), reducing cell damage, activating mitochondrial apoptotic pathways, and 
inhibiting cell apoptosis (Guan et al., 2015). Regulating the excessive activation of the RAAS and cytokine production 
may represent major roles in the inhibition of cardiomyocyte hypertrophy (Shi et al., 2009, Yang et al., 2013).  
The preliminary results of the present study indicated that astragaloside inhibited ET-1-induced cardiomyocyte 
hypertrophy. The flow cytometry results showed that ET-1 induced apoptosis in cardiomyocytes and that astragaloside 
and vitamin D significantly ameliorated ET-1-induced cardiomyocyte apoptosis. Astragaloside influenced the VDR, 
CYP27B, and CYP24A mRNA expression levels in a dose-dependent manner. This result suggests that astragaloside 
treatment may reverse cardiomyocyte hypertrophy by regulating the levels of relevant factors in the vitamin D axis. 
In summary, our study demonstrated that astragaloside was cardioprotective in cultured cardiomyocytes and 
exerted significant anti-hypertrophic activities at least partially through the vitamin D axis. These findings suggest that 
uncovering the mechanisms of astragaloside are important for the treatment of cardiovascular disease. Therefore, further 
in-depth investigations on astragaloside for cardiomyocyte hypertrophy are needed, especially at the molecular level, to 
provide a safer and more reliable treatment modality for cardiovascular diseases. 
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